---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-050913"
form_type: "8-K"
ticker: "BJDX"
cik: "0001704287"
company_name: "Bluejay Diagnostics, Inc."
filed_at: "2025-06-04T23:59:59+00:00"
generated_at: "2026-05-20T00:00:41.944720+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Bluejay Diagnostics mid-year update: cash $5.7M, headcount cut to 5, seeks $30M+ funding

## Summary
- SYMON-II pivotal sepsis trial enrolling; 510(k) submission planned for Q4 2027, FDA approval target Q3 2028.
- Cash & equivalents $5.7M as of April 30, 2025; Q1 2025 net loss $1.9M, FY2024 net loss $7.7M.
- April 2025 private placement raised $3.8M gross; company aims to raise at least $30M total through FY2027.
- Workforce reduced to 5 employees after CTO departure; cost-saving measures implemented.
- Annual meeting June 18, 2025: board to shrink from 6 to 5, reverse stock split proposals to maintain Nasdaq listing.

## SEC filing metadata
- accession: 0001213900-25-050913
- form_type: 8-K
- ticker: BJDX
- cik: 0001704287
- company_name: Bluejay Diagnostics, Inc.
- filed_at: 2025-06-04T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1704287/000121390025050913/0001213900-25-050913-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1704287/000121390025050913/ea0244646-8k_bluejay.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-050913
- JSON: https://secwatch.observer/filing/0001213900-25-050913.json
- Plain text: https://secwatch.observer/filing/0001213900-25-050913.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.